Want to see SE:QLIFE full AI Analyst Report?
QLIFE Stock Chart & Stats
kr3.01
-kr0.24(-7.59%)
At close: 4:00 PM EST
kr3.01
-kr0.24(-7.59%)
Day’s Range― - ―
52-Week Rangekr1.20 - kr4.89
Previous CloseN/A
Volume24.68K
Average Volume (3M)97.19K
Market Cap
kr55.90M
Enterprise Valuekr27.25M
Total Cash (Recent Filing)kr6.63M
Total Debt (Recent Filing)kr8.71M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding28,874,178
10 Day Avg. Volume81,486
30 Day Avg. Volume97,188
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-126.16
Revenue Forecast (FY)kr116.00M
Bulls Say, Bears Say
Bulls Say
Home-based Diagnostic PlatformQlife's focus on near-patient and home-based diagnostics via the Egoo Health system aligns with a durable healthcare shift toward decentralized testing and remote monitoring. This platform orientation supports recurring test volumes, digital follow-up services, and long-term relevance if adoption scales.
Equity Position ImprovedTrailing-twelve-month equity turning positive marks an important balance-sheet inflection after several periods of negative equity. That improvement reduces immediate insolvency pressure, can widen financing options, and provides more flexibility to execute strategic initiatives over coming months.
Cash Loss Conversion Better Than Accounting LossFCF being ~0.88x of net loss indicates a sizable portion of reported losses are non-cash. This improves actual cash runway versus headline losses, easing near-term liquidity strain and reducing immediate refinancing urgency if negative cash trends stabilize.
Bears Say
Minimal And Shrinking RevenueVery low TTM revenue (239k) and a 27% year-over-year decline signal weak commercial traction and limited market penetration. Such shallow top-line makes scaling costly, leaves fixed costs uncovered, and implies the business requires a material revenue inflection to reach sustainable operations.
Deep Persistent UnprofitabilitySubstantially negative gross profit and operating/net margins (~-82%/-86%) show the cost base far exceeds revenue. These persistent, deep losses suggest structural unprofitability absent strong product-market fit improvements or major cost restructuring, challenging sustainability over months.
High Leverage And Cash BurnSignificant operating cash outflows (TTM OCF -12.7m) and free cash burn, combined with ~8.7m debt against ~1.9m equity (~4.6x), create high refinancing and solvency risk. Continued burn plus leverage limit strategic flexibility and make the company reliant on external funding absent quick improvement.
QLIFE FAQ
What was Qlife Holding AB’s price range in the past 12 months?
Qlife Holding AB lowest stock price was kr1.20 and its highest was kr4.89 in the past 12 months.
What is Qlife Holding AB’s market cap?
Qlife Holding AB’s market cap is kr55.90M.
When is Qlife Holding AB’s upcoming earnings report date?
Qlife Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 24 days.
How were Qlife Holding AB’s earnings last quarter?
Qlife Holding AB released its earnings results on May 13, 2026. The company reported -kr0.719 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.719.
Is Qlife Holding AB overvalued?
According to Wall Street analysts Qlife Holding AB’s price is currently Overvalued.
Does Qlife Holding AB pay dividends?
Qlife Holding AB does not currently pay dividends.
What is Qlife Holding AB’s EPS estimate?
Qlife Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlife Holding AB have?
Qlife Holding AB has 28,874,178 shares outstanding.
What happened to Qlife Holding AB’s price movement after its last earnings report?
Qlife Holding AB reported an EPS of -kr0.719 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.817%.
Which hedge fund is a major shareholder of Qlife Holding AB?
Currently, no hedge funds are holding shares in SE:QLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlife Holding AB
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.